ReviewNature reviews. Clinical oncology2022
Mitigating acute chemotherapy-associated adverse events in patients with cancer.
Review in Nature reviews. Clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07287826 (Study for Dexamethasone Mouthwash in Lowering Episodes of Oral Mucositis Among Patients With Cancer), which is not on this map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study for Dexamethasone Mouthwash in Lowering Episodes of Oral Mucositis Among Patients With Cancer: The SMILE Study
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Effects of high-protein supplementation during cancer therapy: a systematic review and meta-analysis.The American journal of clinical nutrition · 2024Pooled it
- Unplanned hospital presentations in oncology patients receiving chemotherapy: a secondary analysis of a randomized controlled trial to explore opportunities for improving supportive care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Trial
- Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Trial
- Article
- Chemical-Sensing Catheters for Long-Term and Personalized Therapeutic Management.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Chemotherapy-driven gut microbiota remodeling in ovarian cancer: a prospective longitudinal study.Journal of translational medicine · 2026Article
- Chemotherapy induces tissue NADbioRxiv : the preprint server for biology · 2026Article
- Psychological Factors and Treatment Experiences Associated With Chemotherapy Side-Effect Expectations and Symptom Severity: A Prospective Longitudinal Study.Cancer medicine · 2026Article
- Zinc-Doped Calcium Phosphate Nanoagonists Amplifies cGAS-STING Signaling for Boosting Pyroptosis-Induced Cancer Immunotherapy.Journal of functional biomaterials · 2026Article
- Article
- A Novel Hydrophilic Colloidal Polysaccharide fromFoods (Basel, Switzerland) · 2026Article
- Antibody-drug conjugates in cancer treatment: from molecular design to clinical implementation.The Lancet regional health. Europe · 2026Review
- Article
- Patient-Perceived Overall Side Effect Bother at and After Cancer Treatment Discontinuation: An Analysis Using Commercial Cancer Trial Data.Therapeutic innovation & regulatory science · 2026Article
- Role of solute carrier transporters in the biodistribution and toxicity of chemotherapeutic drugs.Pharmacological reviews · 2026Review
- Exploiting intracellular oncogenic proteins to release cytotoxins.RSC medicinal chemistry · 2026Article
- Construction of PANoptosis-Inhibiting Carbonized Polymer Dots via Machine Learning Potential for Mitigating Chemodrug-Induced Nephrotoxicity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Impact ofBiology · 2026Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the enthusiasm surrounding novel targeted agents and immunotherapies, chemotherapy remains the mainstay treatment for most human malignancies, either alone or in combination. Yet, the burden of chemotherapy-associated adverse events (CAAEs) remains high and, importantly, is associated with considerable morbidity, mortality and costs that affect patients across multiple dimensions, including physical, emotional and social functioning. CAAEs can directly affect patient outcomes and indirectly increase the risk of cancer recurrence by compromising treatment intensity and continuity. Systematic efforts to identify and critically summarize the evidence on management approaches for CAAEs remain limited. Herein, we review the most common acute CAAEs having a major effect on survival, quality of life, function and/or continuation of optimal therapy. We focus on selected acute toxicities that occur during treatment, summarizing their underlying pathophysiology, multifactorial aetiologies, evidenced-based treatments, prevention strategies and management recommendations. We also summarize the available evidence on risk factors, validated risk assessment tools and other efforts to optimize symptom control in patients most likely to benefit in order to personalize the prevention and treatment of acute CAAEs. Finally, we discuss innovative symptom monitoring and supportive care interventions that are under development to further improve the outcomes of patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.